This is a Validated Antibody Database (VAD) review about Rhesus mon.. TP53, based on 27 published articles (read how Labome selects the articles), using TP53 antibody in all methods. It is aimed to help Labome visitors find the most suited TP53 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
TP53 synonym: cellular tumor antigen p53; P53; tumor suppressor p53

others
  • western blot; human; loading ...; fig 1c
 TP53 antibody (Thermo Fisher, DO-1) was used in western blot on human samples (fig 1c). Oncotarget (2018) ncbi
Invitrogen
mouse monoclonal (DO-1)
  • western blot; human; loading ...; fig 4a
Invitrogen TP53 antibody (Labvision, MS-187P) was used in western blot on human samples (fig 4a). Cell Rep (2018) ncbi
mouse monoclonal (DO-1)
  • western blot; human; loading ...; fig 1c
Invitrogen TP53 antibody (Thermo Fisher, DO-1) was used in western blot on human samples (fig 1c). Oncotarget (2018) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry - frozen section; human; 1:100; loading ...; fig 1a
Invitrogen TP53 antibody (Invitrogen, DO1) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig 1a). Science (2018) ncbi
mouse monoclonal (DO-1)
  • immunocytochemistry; rat; 1:100; loading ...; fig 1b
In order to compare the efficiency of fascaplysin with other drugs used to treat glial tumors, Invitrogen TP53 antibody (Thermo Fisher Scientific, AHO0152) was used in immunocytochemistry on rat samples at 1:100 (fig 1b). Oncol Lett (2017) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
In order to analyze high-risk HPV incidence, prognostic biomarkers, and outcome in HIV-positive and -negative patients with head and neck squamous cell cancer, Invitrogen TP53 antibody (Thermo Scientific, DO-1) was used in immunohistochemistry - paraffin section on human samples (fig 2). Mol Cancer Res (2017) ncbi
mouse monoclonal (DO-1)
  • immunocytochemistry; rat; 1:100; loading ...
In order to study the use of hematopoietic stem cells to treat glioblastoma, Invitrogen TP53 antibody (Thermo, AHO0152) was used in immunocytochemistry on rat samples at 1:100. Mol Med Rep (2016) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry; human; loading ...; fig 1b
In order to correlate 1p/19q codeletion, IDH1 mutation and p53 protein overexpression with prognosis in Turkish anaplastic oligodendroglioma patients treated with adjuvant radiotherapy and temozolomide chemotherapy, Invitrogen TP53 antibody (Thermo Fisher, DO-7+BP53-12) was used in immunohistochemistry on human samples (fig 1b). Turk Neurosurg (2017) ncbi
mouse monoclonal (DO-1)
  • immunocytochemistry; rat; 1:100; fig 1
In order to clarify the interaction between microglial cells and cancer stem cells, Invitrogen TP53 antibody (Novex, Thermo Fisher Scientific, AHO0152) was used in immunocytochemistry on rat samples at 1:100 (fig 1). Oncol Lett (2016) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1i
In order to measure adenosine A1 and A2a receptor expression and determine their association with glioma development and epilepsy, Invitrogen TP53 antibody (Thermo Scientific, DO-7+BP53-12) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1i). Neurochem Res (2016) ncbi
mouse monoclonal (DO-1)
  • western blot; human; loading ...; fig 2a
In order to ask if p53 status of patients with hepatocellular carcinoma affects the efficacy of herpes simplex virus-1 thymidine kinase/ganciclovir therapy, Invitrogen TP53 antibody (NeoMarkers, DO-1) was used in western blot on human samples (fig 2a). Oncotarget (2016) ncbi
mouse monoclonal (DO-1)
  • western blot; human; loading ...; fig s2a
In order to identify and study roles for MAP3K8 in high-grade serous ovarian carcinomas, Invitrogen TP53 antibody (Thermoscientific, MS-187-PO) was used in western blot on human samples (fig s2a). Nat Commun (2015) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry; human; 1:200; fig 3
In order to assess a protocol for acquiring portal venous blood through endoscopic ultrasound, Invitrogen TP53 antibody (Thermo Scientific, p53 Ab-6 (Clone DO-1)) was used in immunohistochemistry on human samples at 1:200 (fig 3). Gastroenterology (2015) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; 1:70; fig 4
In order to study adenosine deaminase and adenosine kinase expression in human glioma and to determine its correlation with glioma associated epilepsy, Invitrogen TP53 antibody (Thermo Fisher Scientific, DO-7+BP53-12) was used in immunohistochemistry - paraffin section on human samples at 1:70 (fig 4). Mol Med Rep (2015) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; fig 1
In order to demonstrate that RUNX2 and p53 independently predict early tumor recurrence in bladder carcinoma patients, Invitrogen TP53 antibody (Thermo Scientific, DO-7+BP53-12) was used in immunohistochemistry - paraffin section on human samples (fig 1). Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; tbl 2
In order to analyze breast cancer subtypes and retrospective analysis of metastatic behaviour, Invitrogen TP53 antibody (Thermo Scientific, DO-7 +BP53-12) was used in immunohistochemistry - paraffin section on human samples (tbl 2). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (DO-1)
  • immunoprecipitation; human
  • western blot; human
In order to study the homo- and heterodimerization of an E3 ligase MDM2, Invitrogen TP53 antibody (Labvision, DO-1) was used in immunoprecipitation on human samples and in western blot on human samples . J Biol Chem (2015) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; 1:200; fig 3a
In order to compare the features of patients with proliferative verrucous leukoplakia and those with conventional squamous cell carcinoma, Invitrogen TP53 antibody (Neomarkers, DO-7+Bp53-12) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 3a). Oral Surg Oral Med Oral Pathol Oral Radiol (2015) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry; human; 1:100
In order to describe a tumor from a patient with oncocytic cystadenoma, Invitrogen TP53 antibody (Lab Vision, DO-7+BP53-12) was used in immunohistochemistry on human samples at 1:100. Medicine (Baltimore) (2014) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry - paraffin section; human; 1:100
In order to assess the prognostic value of immunohistochemical markers in nonhuman primates, Invitrogen TP53 antibody (Thermo Scientific, MS187) was used in immunohistochemistry - paraffin section on human samples at 1:100. Comp Med (2014) ncbi
mouse monoclonal (DO-1)
  • western blot; human; 1:1000
In order to describe a new polymeric-phospholipidic hybrid delivery system which enhanced the accumulation and activity of Dox in all tested cancer cell lines, Invitrogen TP53 antibody (NeoMarkers, Do-1) was used in western blot on human samples at 1:1000. J Biomed Nanotechnol (2014) ncbi
mouse monoclonal (DO-1)
  • western blot; human
Invitrogen TP53 antibody (Invitrogen, CA#AHO0152) was used in western blot on human samples . Arch Biochem Biophys (2014) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry - paraffin section; human; 1:100
  • immunohistochemistry; human; 1:100
In order to study the predictive and prognostic value of a range of biomarkers in pre-treatment biopsies from patients with advanced cancer of the larynx, Invitrogen TP53 antibody (Lab Vision, DO-1) was used in immunohistochemistry - paraffin section on human samples at 1:100 and in immunohistochemistry on human samples at 1:100. Laryngoscope (2014) ncbi
mouse monoclonal (DO-1)
  • immunohistochemistry - paraffin section; human
In order to discuss the role of breast cancer-derived IgG in cancer development, Invitrogen TP53 antibody (Zymed Laboratories, AHO0152) was used in immunohistochemistry - paraffin section on human samples . PLoS ONE (2013) ncbi
mouse monoclonal (DO-7, BP53-12)
  • western blot; mouse; 1:500
In order to study the role of TGF-beta inhibitors in abolishing the resistance of glioblastoma to ionozing radiation therapy, Invitrogen TP53 antibody (Neomarkers, MS-738-P) was used in western blot on mouse samples at 1:500. Cancer Res (2012) ncbi
mouse monoclonal (DO-7, BP53-12)
  • immunohistochemistry - paraffin section; human; 1:2000; tbl 1
In order to correlate various clinicopathological and immunohistological variables to pancreatic ductal adenocarcinoma survival, Invitrogen TP53 antibody (Thermo Scientific, MS-738-7) was used in immunohistochemistry - paraffin section on human samples at 1:2000 (tbl 1). Cell Oncol (Dordr) (2012) ncbi
mouse monoclonal (DO-1)
  • western blot; human; fig 1
In order to develop a method to quantify p53 degradation activity of E6 in vivo and assess HPV variants, Invitrogen TP53 antibody (Invitrogen, AHO0152) was used in western blot on human samples (fig 1). J Virol (2012) ncbi
mouse monoclonal (DO-1)
  • western blot; mouse; fig 7
  • western blot; human; fig 7
In order to examine the role of mitochondrial p32 in ARF-induced apoptosis, Invitrogen TP53 antibody (Lab Vision, DO1) was used in western blot on mouse samples (fig 7) and in western blot on human samples (fig 7). Cancer Cell (2008) ncbi
Articles Reviewed
  1. Leslie P, Franklin D, Liu Y, Zhang Y. p53 Regulates the Expression of LRP1 and Apoptosis through a Stress Intensity-Dependent MicroRNA Feedback Loop. Cell Rep. 2018;24:1484-1495 pubmed publisher
  2. Bernal A, Moltó Abad M, Dominguez D, Tusell L. Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16INK4a-deficient epithelial cells. Oncotarget. 2018;9:27151-27170 pubmed publisher
  3. Pommier A, Anaparthy N, Memos N, Kelley Z, Gouronnec A, Yan R, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018;360: pubmed publisher
  4. Bryukhovetskiy I, Lyakhova I, Mischenko P, Milkina E, Zaitsev S, Khotimchenko Y, et al. Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro. Oncol Lett. 2017;13:738-746 pubmed publisher
  5. Walline H, Carey T, Goudsmit C, Bellile E, D Souza G, Peterson L, et al. High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res. 2017;15:179-188 pubmed publisher
  6. Bryukhovetskiy I, Dyuizen I, Shevchenko V, Bryukhovetskiy A, Mischenko P, Milkina E, et al. Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme. Mol Med Rep. 2016;14:4511-4520 pubmed publisher
  7. Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. Turk Neurosurg. 2017;27:682-689 pubmed publisher
  8. Bryukhovetskiy I, Manzhulo I, Mischenko P, Milkina E, Dyuizen I, Bryukhovetskiy A, et al. Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth. Oncol Lett. 2016;12:1721-1728 pubmed
  9. Huang J, Chen M, Du J, Liu H, He Y, Li G, et al. Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy. Neurochem Res. 2016;41:1774-83 pubmed publisher
  10. Liu X, Wang S, Guo X, Wei F, Yin J, Zang Y, et al. Exogenous p53 and ASPP2 expression enhances rAdV-TK/ GCV-induced death in hepatocellular carcinoma cells lacking functional p53. Oncotarget. 2016;7:18896-905 pubmed publisher
  11. Gruosso T, Garnier C, Abélanet S, Kieffer Y, Lemesre V, Bellanger D, et al. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun. 2015;6:8583 pubmed publisher
  12. Catenacci D, Chapman C, Xu P, Koons A, Konda V, Siddiqui U, et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015;149:1794-1803.e4 pubmed publisher
  13. Huang J, He Y, Chen M, Du J, Li G, Li S, et al. Adenosine deaminase and adenosine kinase expression in human glioma and their correlation with glioma‑associated epilepsy. Mol Med Rep. 2015;12:6509-16 pubmed publisher
  14. Abdelzaher E, Kotb A. High Coexpression of Runt-related Transcription Factor 2 (RUNX2) and p53 Independently Predicts Early Tumor Recurrence in Bladder Urothelial Carcinoma Patients. Appl Immunohistochem Mol Morphol. 2016;24:345-54 pubmed publisher
  15. Savci Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57 pubmed publisher
  16. Leslie P, Ke H, Zhang Y. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization. J Biol Chem. 2015;290:12941-50 pubmed publisher
  17. Akrish S, Ben Izhak O, Sabo E, Rachmiel A. Oral squamous cell carcinoma associated with proliferative verrucous leukoplakia compared with conventional squamous cell carcinoma--a clinical, histologic and immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:318-25 pubmed publisher
  18. BaÅŸak K, KiroÄŸlu K. Multiple oncocytic cystadenoma with intraluminal crystalloids in parotid gland: case report. Medicine (Baltimore). 2014;93:e246 pubmed publisher
  19. Beck A, Brooks A, Zeiss C. Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta). Comp Med. 2014;64:314-22 pubmed
  20. Senkiv Y, Riabtseva A, Heffeter P, Boiko N, Kowol C, Jungwith U, et al. Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin. J Biomed Nanotechnol. 2014;10:1369-81 pubmed
  21. Wilking M, SINGH C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 2014;563:94-100 pubmed publisher
  22. Bradford C, Kumar B, Bellile E, Lee J, Taylor J, D SILVA N, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014;124:179-87 pubmed publisher
  23. Yang B, Ma C, Chen Z, Yi W, McNutt M, Wang Y, et al. Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PLoS ONE. 2013;8:e58706 pubmed publisher
  24. Hardee M, Marciscano A, Medina Ramirez C, Zagzag D, Narayana A, Lonning S, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-?. Cancer Res. 2012;72:4119-29 pubmed publisher
  25. Ottenhof N, Morsink F, Ten Kate F, Van Noorden C, Offerhaus G. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr). 2012;35:119-26 pubmed publisher
  26. Mesplede T, Gagnon D, Bergeron Labrecque F, Azar I, Sénéchal H, Coutlee F, et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol. 2012;86:94-107 pubmed publisher
  27. Itahana K, Zhang Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell. 2008;13:542-53 pubmed publisher